ReviewClinical therapeutics2016
Neonatal Gastrointestinal and Respiratory Microbiome in Cystic Fibrosis: Potential Interactions and Implications for Systemic Health.
Review in Clinical therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- From Cure to Crisis: Understanding the Evolution of Antibiotic-Resistant Bacteria in Human Microbiota.Biomolecules · 2025Review
- Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.Journal of pediatric gastroenterology and nutrition · 2024Article
- Impact of high-dose cholecalciferol (vitamin D3) and inulin prebiotic on intestinal and airway microbiota in adults with cystic fibrosis: A 2 × 2 randomized, placebo-controlled, double-blind pilot study.Journal of clinical & translational endocrinology · 2024Article
- Comparison of intestinal and pharyngeal microbiota in preterm infants on the first day of life and the characteristics of pharyngeal microbiota in infants delivered by cesarean section or vaginally.Frontiers in pediatrics · 2024Article
- Observational
- Resilience and stability of the CF- intestinal and respiratory microbiome during nutritional and exercise intervention.BMC microbiology · 2023Article
- Temporal changes of the respiratory microbiota as cats transition from health to experimental acute and chronic allergic asthma.Frontiers in veterinary science · 2022Article
- Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis.Metabolites · 2021Review
- Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis.Pediatric pulmonology · 2020Article
- Regulation Effect of a Chinese Herbal Formula on Flora and Mucosal Immune Secretory Immunoglobulin A in Rats.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Early-Life Intestine Microbiota and Lung Health in Children.Journal of immunology research · 2017Review
- Oral Probiotics Alter Healthy Feline Respiratory Microbiota.Frontiers in microbiology · 2017Article
- Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease.Molecular and cellular pediatrics · 2016Review
- The fermentation product 2,3-butanediol alters P. aeruginosa clearance, cytokine response and the lung microbiome.The ISME journal · 2016Article
- The CF gastrointestinal microbiome: Structure and clinical impact.Pediatric pulmonology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purposeThe gastrointestinal microbiome plays a critical role in nutrition and metabolic and immune functions in infants and young children and has implications for lifelong health. Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) mutations in CF result in viscous mucous production, frequent exposure to antibiotics, and atypical colonization patterns, resulting in an evolving dysbiosis of the gastrointestinal and respiratory microsystems; dysbiosis in CF results in systemic inflammation, chronic infection, and dysregulation of immune function. Dysbiosis in both the respiratory system and gut contributes to undernutrition, growth failure, and long-term respiratory and systemic morbidity in infants and children with CF. Understanding the role that the gut and respiratory microbiome plays in health or disease progression in CF will afford opportunities to better identify interventions to affect clinical changes.
methodsSummary was done of the pertinent literature in CF and the study of the microbiome and probiotics.
findingsNew studies have identified bacteria in the respiratory tract in CF that are typically members of the intestinal microbiota, and enteral exposures to breast milk and probiotics are associated with prolonged periods of respiratory stability in CF. IMPLICATIONS: Understanding the complex interactions between the CFTR mutations, microbial colonization, and mucosal and systemic immunity is of major importance to inform new treatment strategies (such as restoring a healthier microbiome with probiotics or dietary interventions) to improve nutritional status and immune competence and to decrease morbidity and mortality in CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.